The influence of antisense oligonucleotide length on dystrophin exon skipping.
about
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applicationsDiscovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral ResistanceAntisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistriesProgress toward therapy with antisense-mediated splicing modulationAntisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patientInvestigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular DystrophyDynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.Rational design of antisense oligomers to induce dystrophin exon skipping.Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching.Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophyAntisense oligonucleotide induction of progerin in human myogenic cellsDetection of internal exon deletion with exon Del.In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophyDeletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.Targeted exon skipping to address "leaky" mutations in the dystrophin gene.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsImproved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis.Antisense suppression of donor splice site mutations in the dystrophin gene transcript.Targeted exon skipping to correct exon duplications in the dystrophin gene.Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene.Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.HA117 endows HL60 cells with a stem-like signature by inhibiting the degradation of DNMT1 via its ability to down-regulate expression of the GGL domain of RGS6A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic miceOptimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.Correcting the NLRP3 inflammasome deficiency in macrophages from autoimmune NZB mice with exon skipping antisense oligonucleotides.Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy.An amphipathic trans-acting phosphorothioate DNA element delivers uncharged PNA and PMO nucleic acid sequences in mammalian cellsQuantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Designing Effective Antisense Oligonucleotides for Exon Skipping.Amphipathic trans-acting phosphorothioate DNA elements mediate the delivery of uncharged nucleic acid sequences in mammalian cellsNS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular DystrophyShorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD
P2860
Q24682555-404A61C0-09AA-4205-800D-C538EB29EE63Q27316994-8C4F4D88-6867-42FA-B194-9622536BFF9BQ27480935-1BDDA334-4BF8-4ACA-BB9F-B32A45E6CF92Q27489807-A1DA9B08-FFD1-4904-8987-115724D8A2C9Q28475196-271A0EA9-9FC0-4A91-9576-2798FD87960DQ28598287-3DAED3D5-D40A-4FD3-BB48-94F1AF260E78Q33325470-7FD95ACC-F263-4358-BE92-79A122D5D5B1Q33713852-0D457F8E-00F1-4DC9-A79A-5C5B07682E6CQ34052338-88A4BEF3-0139-4FA1-88DA-D80B6102C36FQ34349200-7536E0BB-FC9E-49A0-B1AF-5537F4C88916Q34695728-8FAA74D8-5BA8-407F-9DA6-408EB8A4A2E3Q35180565-E70C1CE5-56F5-41E5-93EF-5E6BB2532BC0Q35342121-FD232A47-BC73-4CD3-85F1-84702AD0C5A7Q35588627-38A81F1B-8C98-4682-A57C-6678F305BD7BQ35888871-C60E66D1-AF09-4661-965F-C249A64FA6BCQ36114216-330FFC75-ED3E-4712-99CA-84B6E7A30DCEQ36403759-EF300BB8-40B5-472B-83CE-0DAC017F068EQ36925191-FDD08294-CF6A-409E-85E0-4370B49EC177Q36972091-07EB49FF-62E4-48DE-822B-F09F362CABCEQ37137973-99B769E8-A4D9-4C72-8F0B-F528CE6EB5E0Q37398103-8BCA22A5-A6D6-4FE1-877B-8B06AA953640Q37695543-2688150A-886C-4A5F-8C07-38CA51E42716Q38357434-87661E7F-FA44-428C-A5D3-C2755C80F6ECQ38360555-5322F823-0914-423B-8112-098C9F97D77DQ38698556-5C9694CC-860E-4FF7-9AFA-21CDB53985BDQ39350652-C211A8FB-50F8-4E7C-B450-1A9846042C86Q39882118-DFD76574-037D-4DE0-86B6-98BE7ED5C516Q40809647-08E6D319-E268-4E75-A156-BF3FC6F61232Q41191227-15D1F402-5664-4596-A030-BB341D27F275Q42143713-67D0D854-0B49-4F32-A73A-33932A9780B3Q45945952-777502F9-6A91-40C2-83DD-C8F4E1B3C20BQ47606988-D6A1ABEE-51DA-4AE1-BF70-4CFE93511CC9Q56115525-A8FACEE8-B1CD-4044-85D0-7AEE3D984B20Q58549842-BDC32D78-8751-4DCF-8170-F9084DE2C464Q58577259-F07AAE94-E368-4705-8612-467F7AF55643
P2860
The influence of antisense oligonucleotide length on dystrophin exon skipping.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@ast
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@en
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@nl
type
label
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@ast
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@en
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@nl
prefLabel
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@ast
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@en
The influence of antisense oligonucleotide length on dystrophin exon skipping.
@nl
P2093
P356
P1433
P1476
The influence of antisense oligonucleotide length on dystrophin exon skipping
@en
P2093
K Honeyman
P L Harding
S D Wilton
P304
P356
10.1038/SJ.MT.6300006
P50
P577
2007-01-01T00:00:00Z